Ligand validation:5BU3

4W9: (4S,4aS,6aS,8R,9R,10aR,13R,14aS,18aR,18bR)-9-ethyl-4,8,19-trihydroxy-10a,12,13,18a-tetramethyl-2,3,4,4a,5,6,6a,7,8,9,10,10a,13,14,18a,18b-hexadecahydro-1H-14a,17-(metheno)benzo[b]naphtho[2,1-h]azacyclododecine-16,18(15H,17H)-dione

4W9 is a Ligand Of Interest in 5BU3 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5BU3_4W9_D_203	88%	16%	0.091	0.968	1.73	2.13	5	11	0	0	100%	1
5BU3_4W9_A_203	75%	15%	0.113	0.947	1.71	2.25	4	11	0	0	100%	1
5BU3_4W9_C_205	61%	16%	0.138	0.929	1.59	2.3	3	9	0	0	100%	1
5BU3_4W9_B_201	45%	14%	0.177	0.91	1.63	2.42	4	10	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.